Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Investigation of the Metabolism and Pharmacokinetics of 10 mg [14C] BI 1356 Administered Orally Compared to 5 mg [14C] BI 1356 Administered Intravenously in Healthy Male Volunteers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02183610
Recruitment Status : Completed
First Posted : July 8, 2014
Last Update Posted : July 8, 2014
Sponsor:
Information provided by (Responsible Party):
Boehringer Ingelheim

Brief Summary:
To determine the basic pharmacokinetics of BI 1356 BS, its metabolite CD 1750 XX and radioactivity including excretion mass balance, excretion pathways and metabolism following the intravenous and oral administration of [14C] BI 1356 BS

Condition or disease Intervention/treatment Phase
Healthy Drug: [14C] BI 1356 as oral (p.o.) solution Drug: [14C] BI 1356 solution for i.v. infusion Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 12 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Investigation of the Metabolism and Pharmacokinetics of 10 mg [14C] BI 1356 Administered Orally Compared to 5 mg [14C] BI 1356 Administered Intravenously in Healthy Male Volunteers in an Open Label, Single-dose and Parallel Study Design
Study Start Date : July 2006
Actual Primary Completion Date : September 2006

Resource links provided by the National Library of Medicine

Drug Information available for: Linagliptin

Arm Intervention/treatment
Experimental: [14C] BI 1356 as oral (p.o.) solution Drug: [14C] BI 1356 as oral (p.o.) solution
Experimental: [14C] BI 1356 solution for i.v. infusion Drug: [14C] BI 1356 solution for i.v. infusion



Primary Outcome Measures :
  1. Comparison of individual time course profiles of [14C] radioactivity in whole blood, plasma, urine and faeces [ Time Frame: before and up to 264 h after drug administration ]
  2. Comparison of individual time course profiles of BI 1356 BS and its metabolite CD 1750 XX in plasma and urine [ Time Frame: before and up to 264 h after drug administration ]
  3. Rate and extent of excretion mass balance based on the total radioactivity in urine and faeces [ Time Frame: prior to and up to 120 h after start of administration ]
  4. CBlood cell/Cplasma ratio of [14C] -radioactivity [ Time Frame: 1:30, 3, 24 and 72 h after drug administration ]
  5. Measurement of the plasma protein binding of total [14C] radioactivity in human plasma samples ex vivo [ Time Frame: 1:30 and 3 hours post drug administration ]
  6. Cmax (maximum concentration of the analyte(s) in plasma) [ Time Frame: before and up to 264 h after drug administration ]
  7. tmax (time from dosing to the maximum concentration of the analyte(s) in plasma) [ Time Frame: before and up to 264 h after drug administration ]
  8. AUC0-tz (area under the concentration-time curve of the analyte(s) in plasma over the time interval from 0 to the time of the last quantifiable data point) [ Time Frame: before and up to 264 h after drug administration ]
  9. AUC0-infinity (area under the concentration-time curve of the analyte(s) in plasma over the time interval from 0 to infinity) [ Time Frame: before and up to 264 h after drug administration ]
  10. λz (terminal rate constant in plasma) [ Time Frame: before and up to 264 h after drug administration ]
  11. t1/2 (terminal half-life of the analyte(s) in plasma) [ Time Frame: before and up to 264 h after drug administration ]
  12. MRTpo and MRT, respectively (mean residence time of the analyte(s) in the body after p.o. and i.v. administration) [ Time Frame: before and up to 264 h after drug administration ]
  13. CL/F (apparent/total clearance of the analyte(s) in plasma following extravascular and intravenous administration) [ Time Frame: before and up to 264 h after drug administration ]
  14. Vz/F (apparent volume of distribution during the terminal phase λz following an extravascular or intravenous administration (F=1) respectively) [ Time Frame: before and up to 264 h after drug administration ]
  15. feurine,0-tz (amount of analyte excreted in urine within the time interval zero to tz (=120 h) in % of dose) [ Time Frame: prior to and up to 120 h after start of administration ]
  16. fefaeces,0-tz (amount of analyte excreted in faeces within the time interval zero to tz (=120 h) in % of dose) [ Time Frame: up to 120 h after drug administration ]
  17. CLR,0-tz (renal clearance of analyte) [ Time Frame: prior to and up to 120 h after start of administration ]
  18. Fa (drug absorption based on radioactivity data) [ Time Frame: up to 264 h after drug administration ]

Secondary Outcome Measures :
  1. Number of patients with adverse events [ Time Frame: up to 47 days ]
  2. Global assessment of tolerability by investigator on a 4-point scale [ Time Frame: on day 12 during ambulant visit or on day of discharge on day 13, 14 or 15 ]
  3. Evaluation of local tolerability of the infusion by investigator on a 6-point scale [ Time Frame: after start of infusion up to day 15 ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   30 Years to 60 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

- Healthy males according to the following criteria: Based upon a complete medical history, including the physical examination, vital signs Blood Pressure (BP), Pulse Rate (PR)), 12-lead Electrocardiogram (ECG), clinical laboratory tests

  • Age >=30 and Age <=60 years
  • BMI >=18.5 and BMI <=29.9 kg/m2 (Body Mass Index)
  • Signed and dated written informed consent prior to admission to the study in accordance with Good clinical practice (GCP) and the local legislation

Exclusion Criteria:

  • Any finding of the medical examination (including BP, PR and ECG) deviating from normal and of clinical relevance
  • Any evidence of a clinically relevant concomitant disease
  • Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
  • Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders
  • History of relevant orthostatic hypotension, fainting spells or blackouts
  • Chronic or relevant acute infections
  • History of relevant allergy/hypersensitivity (including allergy to drug or its excipients)
  • Intake of drugs with a long half-life (> 24 hours) within at least one month or less than 10 half-lives of the respective drug prior to administration or during the trial
  • Use of drugs which might reasonably influence the results of the trial based on the knowledge at the time of protocol preparation within 10 days prior to administration or during the trial
  • Participation in another trial with an investigational drug within two months prior to administration or during the trial
  • Smoker (> 10 cigarettes or > 3 cigars or > 3 pipes/day)
  • Inability to refrain from smoking during the stay in the trial centre
  • Alcohol abuse (more than 60 g/day)
  • Drug abuse
  • Blood donation (more than 100 mL within four weeks prior to administration or during the trial)
  • Excessive physical activities (within one week prior to administration or during the trial)
  • Any laboratory value outside the reference range that is of clinical relevance
  • Inability to comply with dietary regimen of study centre
  • A marked baseline prolongation of QT/QTc interval (e.g., repeated demonstration of a QTc interval >450 ms);
  • Male subjects must agree to minimize the risk of female partners becoming pregnant from the dosing day until 3 months after the completion of the study. Acceptable methods of contraception for male volunteers include a vasectomy no less than 3 months prior to dosing, barrier contraception or a medically accepted contraceptive method. For female partners of male volunteers, acceptable methods of contraception include intra-uterine device, tubal ligation, hormonal contraceptive since at least two months and diaphragm with spermicide

Exclusion criteria specific for this study:

  • Veins unsuitable for infusion and blood sampling
  • PR interval >220 ms or QRS interval >120 ms
  • Female gender

Layout table for additonal information
Responsible Party: Boehringer Ingelheim
ClinicalTrials.gov Identifier: NCT02183610    
Other Study ID Numbers: 1218.7
First Posted: July 8, 2014    Key Record Dates
Last Update Posted: July 8, 2014
Last Verified: July 2014
Additional relevant MeSH terms:
Layout table for MeSH terms
Linagliptin
Pharmaceutical Solutions
Hypoglycemic Agents
Physiological Effects of Drugs
Incretins
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Dipeptidyl-Peptidase IV Inhibitors
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action